.png)
AnthiaCumming/E+ via Getty Images
- Schrödinger (NASDAQ:SDGR) said that the U.S. FDA granted Fast Track status to its MALT1 inhibitor, SGR-1505, for treating adults with Waldenström macroglobulinemia who have not responded to at least two previous therapies.
- Fast-track designation allows a faster timeline for the
English (US) ·